How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Save this article to read it later. Find this story in your account’s ‘Saved for Later’ section. We are still updating this guide as we learn more about what’s in the Justice Department’s massive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results